JNJ-87801493
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for JNJ-87801493, covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer [Phase 1]